Merus N.V. (MRUS)
- Previous Close
53.33 - Open
53.25 - Bid 55.33 x 100
- Ask 55.45 x 100
- Day's Range
53.25 - 55.89 - 52 Week Range
19.81 - 61.61 - Volume
636,636 - Avg. Volume
927,920 - Market Cap (intraday)
3.734B - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-2.73 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
84.75
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
www.merus.nlRecent News: MRUS
Performance Overview: MRUS
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRUS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRUS
Valuation Measures
Market Cap
3.60B
Enterprise Value
3.27B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
76.05
Price/Book (mrq)
10.30
Enterprise Value/Revenue
85.43
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.89%
Return on Equity (ttm)
-52.79%
Revenue (ttm)
38.34M
Net Income Avi to Common (ttm)
-149.65M
Diluted EPS (ttm)
-2.73
Balance Sheet and Cash Flow
Total Cash (mrq)
337.5M
Total Debt/Equity (mrq)
3.30%
Levered Free Cash Flow (ttm)
-129.25M
Research Analysis: MRUS
Company Insights: MRUS
MRUS does not have Company Insights
Research Reports: MRUS
Daily – Vickers Top Buyers & Sellers for 10/12/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/11/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/02/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/25/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.